Cytokinetics Inc CYTK:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:04 PM EDT
38.79UNCH (UNCH)
Volume
33,319
Close
38.79quote price arrow up+0.14 (+0.36%)
Volume
1,385,611
52 week range
17.72 - 47.90
Loading...
  • Open38.16
  • Day High39.17
  • Day Low36.81
  • Prev Close38.65
  • 52 Week High47.90
  • 52 Week High Date12/30/21
  • 52 Week Low17.72
  • 52 Week Low Date07/14/21

Key Stats

  • Market Cap3.322B
  • Shares Out85.65M
  • 10 Day Average Volume1.03M
  • Dividend-
  • Dividend Yield-
  • Beta1.22
  • YTD % Change-15.29

KEY STATS

  • Open38.16
  • Day High39.17
  • Day Low36.81
  • Prev Close38.65
  • 52 Week High47.90
  • 52 Week High Date12/30/21
  • 52 Week Low17.72
  • 52 Week Low Date07/14/21
  • Market Cap3.322B
  • Shares Out85.65M
  • 10 Day Average Volume1.03M
  • Dividend-
  • Dividend Yield-
  • Beta1.22
  • YTD % Change-15.29

RATIOS/PROFITABILITY

  • EPS (TTM)-3.22
  • P/E (TTM)-12.04
  • Fwd P/E (NTM)-9.09
  • EBITDA (TTM)-217.679M
  • ROE (TTM)-279.90%
  • Revenue (TTM)65.03M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-396.22%
  • Debt To Equity (MRQ)170.29%

EVENTS

  • Earnings Date08/03/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cytokinetics Inc

There is no recent news for this security.

Profile

MORE
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. It is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. It is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates are: omecamtiv mecarbil, a cardiac myosin activator for the treatment of heart failure with reduced...
John Henderson M.D.
Independent Chairman of the Board
Robert Blum
President, Chief Executive Officer, Director
Ching Jaw
Chief Financial Officer, Senior Vice President
Robert Wong
Chief Accounting Officer, Vice President
Fady Malik M.D., Ph.D.
Executive Vice President - Research and Development
Address
350 OYSTER POINT BOULEVARD, .
South San Francisco, CA
94080
United States

Top Peers

SYMBOLLASTCHG%CHG
NTLA
Intellia Therapeutics Inc
47.71+0.77+1.64%
CERE
Cerevel Therapeutics Holdings Inc
24.44+0.82+3.47%
ZLAB
Zai Lab Ltd
35.72+1.21+3.51%
APLS
Apellis Pharmaceuticals Inc
44.48+0.96+2.21%
CVAC
CureVac NV
19.41+1.40+7.77%